Sign in

Lily Young

Research Analyst at Leerink Partners

Lily Young is an Equity Research Analyst at Leerink Partners, focusing on coverage within the healthcare and biotechnology sectors. She covers major public companies in pharma and biotech, leveraging deep sector knowledge to provide actionable insights for institutional clients, though detailed performance metrics or public rankings like TipRanks are not available. Lily began her career in investment research shortly after graduating and has advanced at Leerink Partners, with no public record indicating prior positions at other firms. She holds Series 7 and 63 securities licenses and is registered with FINRA as required for her analyst role.

Lily Young's questions to IONIS PHARMACEUTICALS (IONS) leadership

Question · Q1 2025

Lily Young, on for Mani Foroohar, asked for more detail on the distribution of TRYNGOLZA patients between newly and previously diagnosed, and how that mix is expected to evolve.

Answer

Chief Global Product Strategy Officer Kyle Jenne stated that while specific patient numbers would not be disclosed, the company is encouraged by new patient identification and expects incremental additions quarterly. CEO Brett Monia clarified that going forward, growth depends on identifying new patients, as the initial bolus of known and clinical trial patients has been largely addressed. Chief Commercial Officer Jonathan Birchall added that growing awareness is motivating physicians to diagnose more actively.

Ask follow-up questions

Fintool

Fintool can predict IONIS PHARMACEUTICALS logo IONS's earnings beat/miss a week before the call

Let Fintool AI Agent track Lily Young for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free